Lilly blames slower-than-expected growth for 2024 sales miss
Bio Pharma Dive
JANUARY 14, 2025
The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ramp-up in sales this year.
This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Bio Pharma Dive
JANUARY 14, 2025
The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ramp-up in sales this year.
Bio Pharma Dive
JULY 17, 2024
Jefferies analyst Andrew Tsai views growing sales for J&J’s depression treatment as evidence that psychedelics like it can be commercially viable.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
MAY 13, 2025
Abeonas deal value is in line with recent voucher sale transactions amid uncertain times in rare disease drug development.
Bio Pharma Dive
OCTOBER 30, 2024
Third quarter Mounjaro and Zepbound sales, while up substantially versus the same period last year, grew little compared to the second quarter amid inventory decreases in the U.S.
Speaker: Steve Goldstein, Sales Leader
Are you currently in sales, or involved in a business that depends on strong sales results? What about the extremely competitive world of medical device sales? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC., Toastmasters Champion.
Bio Pharma Dive
APRIL 13, 2023
The Danish drugmaker nearly doubled the 2023 forecasts for Wegovy and Ozempic in the latest indicator of the sales potential of an emerging and competitive class of weight loss drugs.
Bio Pharma Dive
NOVEMBER 9, 2022
While many companies are still unsure of the Inflation Reduction Act's effects, some have begun to warn investors about the likelihood of lower sales and reduced profitability.
Bio Pharma Dive
AUGUST 1, 2024
The biotech cited competitive pressure and “very low” expected sales in Europe for its latest guidance cut, which sent shares down by nearly 20%.
Bio Pharma Dive
DECEMBER 22, 2021
Leqvio, which Novartis acquired for nearly $10 billion two years ago, arrives with high sales expectations. But uptake could be slow as insurers and doctors weigh the drug's safety and cost-effectiveness.
Bio Pharma Dive
NOVEMBER 7, 2024
Elevidys sales have increased since the FDA made a controversial choice to expand the therapy's use. Now, Sarepta is abandoning a successor to its drug Exondys 51, citing an “evolving" treatment landscape.
Bio Pharma Dive
JANUARY 6, 2023
The gene therapy developer will receive $95 million from Bristol Myers Squibb, slightly less than it got in the recent sale of another priority review voucher.
Bio Pharma Dive
NOVEMBER 2, 2023
The rival companies reported strong quarterly sales growth for their latest products, which could face off as weight loss treatments next year.
Bio Pharma Dive
JULY 27, 2022
A manufacturing issue for Breyanzi, meanwhile, impacted sales. Demand has increased faster than Bristol Myers can make Abecma, although the company said supply is improving.
Bio Pharma Dive
MAY 1, 2024
Sales of the shingles vaccine Shingrix and the RSV shot Arexvy helped fuel quarterly revenue totals that surpassed analyst expectations, though the company warned momentum could slow in the months ahead.
Bio Pharma Dive
MAY 12, 2025
The biotech has quickly turned a cell therapy approval into one of the more lucrative recent sales for a priority review voucher, which companies can use to fast track drug reviews.
Bio Pharma Dive
MAY 1, 2024
Sales of the transthyretin amyloidosis treatment widely beat Wall Street forecasts in the first quarter. The company aims to extend its patent exclusivity.
Bio Pharma Dive
APRIL 30, 2024
Supply continues to be tight, however, and the company anticipates further sales growth to be limited by how quickly it can bring on additional production capacity.
Bio Pharma Dive
JANUARY 24, 2023
The drugmaker reported fourth quarter revenue that fell short of forecasts, but reiterated confidence in reaching a $60 billion pharmaceutical sales goal.
Pharmaceutical Technology
JANUARY 31, 2025
Roche achieved a sales growth of 7% (3% in CHF) in 2024, citing strong demand for pharmaceutical products.
Pharmaceutical Technology
MAY 2, 2024
Novo Nordisk noted a 22% boost in sales owing to increased sales of GLP-1 agonists and other obesity products.
Bio Pharma Dive
MAY 2, 2024
First quarter sales of the in-demand obesity drug were down slightly compared to the fourth quarter last year, as the company tries to meet demand.
Pharmaceutical Technology
AUGUST 9, 2024
Days after competitor Novo Nordisk posted underwhelming Wegovy sales, Eli Lilly cited “strong performance” for Zepbound and Mounjaro.
World of DTC Marketing
JUNE 18, 2025
However, Medical Affairs people are often limited by budgets because management prefers to invest more in marketing and sales people. Sales Leadership: Overpromised, Underprepared While sales reps often get blamed for a poor launch, the real issue usually lies with sales leadership. Did they hire the right people?
Bio Pharma Dive
AUGUST 8, 2024
Company executives claimed “unprecedented demand” for the Duchenne gene therapy will soon cause a sales surge, countering a dip in quarterly sales and financial projections that raised concerns among investors.
Bio Pharma Dive
FEBRUARY 3, 2023
The biotech recently stopped a trial of its experimental conditioning regimen over safety concerns. Now it’s halting further development work as it undertakes a strategic review.
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 2, 2024
per cent growth in sales of generic medicines at Maximum Retail Price (MRP) value in the month of August, as compared to the sales same month a year […]
Pharmaceutical Technology
JUNE 5, 2025
Regeneron and Sanofis blockbuster Dupixent has transformed the atopic dermatitis market, with future disruptors in the pipeline.
Bio Pharma Dive
OCTOBER 28, 2022
After a slow start, Gilead’s CAR-T business is growing fast, enabling it to pull ahead of rival cell therapy developers like Bristol Myers Squibb and Johnson & Johnson.
Bio Pharma Dive
FEBRUARY 17, 2022
The layoffs — which, according to Yumanity, should be completed by April — are part of a larger restructuring effort meant to reduce costs after a recent setback to the company's most advanced drug program.
Bio Pharma Dive
SEPTEMBER 5, 2023
The FDA-approved therapy, called Palforzia, was little used, leading Nestle to abandon a business it had secured in a $2.6 billion deal three years ago.
Bio Pharma Dive
APRIL 2, 2024
Stalking horse bidder Merz Therapeutics could get rights to Acorda’s three marketed drugs if its $185 million proposal holds.
Bio Pharma Dive
SEPTEMBER 30, 2021
The acquisition is notable for Merck, which is under pressure to diversify its business beyond the cancer drug Keytruda and has typically favored smaller buyouts.
Bio Pharma Dive
NOVEMBER 2, 2022
Manufacturing problems continue to weigh on Novo’s Wegovy launch as competition looms from Eli Lilly’s fast-selling diabetes medicine Mounjaro.
Bio Pharma Dive
MAY 1, 2025
Rezdiffra sales reached $137 million for the quarter, beating consensus analyst estimates by more than $20 million and continuing a faster-than-expected drug launch.
Bio Pharma Dive
AUGUST 7, 2024
Quarterly revenue from Ozempic and Wegovy missed Wall Street estimates by about 9%, concerning some analysts and causing a stock sell-off costing the Danish drugmaker tens of billions in market value.
Bio Pharma Dive
FEBRUARY 23, 2024
The company earned only $3.5 million last year from its Roctavian treatment, far below the $50 million to $150 million range it had forecast eight months ago.
Bio Pharma Dive
JUNE 1, 2023
The biotech will price its biosimilar Yusimry at 85% below Humira’s list price when it launches next month, and charge even less if bought through Mark Cuban’s pharmacy.
Bio Pharma Dive
JUNE 27, 2024
Novo will pay $38 million in cash under the deal, which will also see 2seventy employees working on the program transfer to the Danish drugmaker.
Bio Pharma Dive
OCTOBER 2, 2024
Biosimilar competition to aging blockbusters will erode a large chunk of the pharma giant’s top line over the next few years.
Bio Pharma Dive
OCTOBER 25, 2022
Treatment is now mostly of infants newly diagnosed with spinal muscular atrophy, as many of those previously eligible either already received Zolgensma or other drugs from Biogen and Roche.
Bio Pharma Dive
SEPTEMBER 27, 2023
Laboratoires Théa terminated its planned purchase of ProQR’s sepofarsen after certain ProQR personnel opted against working for the French company.
Bio Pharma Dive
NOVEMBER 1, 2022
Company executives highlighted the “viral nature” of demand for Mounjaro, which was approved in May for diabetes and has also shown a strong weight-loss benefit in clinical testing.
Bio Pharma Dive
NOVEMBER 22, 2024
The restructuring follows the company's receipt of a letter from the FDA citing "deficiencies" in its approval application for diabetes drug Zynquista.
AuroBlog - Aurous Healthcare Clinical Trials blog
SEPTEMBER 10, 2024
In order to avoid environmental hazards due to pharmaceutical products, the Department of Pharmaceuticals (DoP) is thinking of framing a ‘Disposal Policy’ for removing the unused and date-expired drugs from the sale premises and from the households.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content